Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) A modified antibody of class IgG with FcRn binding affinity and/or serum half-life increased relative to that of an unmodified antibody, the modified antibody comprising a variable region from daclizumab and a heavy chain constant region, wherein the heavy chain constant region comprises ~~at least amino acid residue 250, EU numbering, is~~ glutamic acid or glutamine at amino acid residue 250 and leucine or phenylalanine at amino acid residue 428, EU numbering~~, is leucine or phenylalanine, wherein the FcRn binding affinity and/or serum half-life of said modified antibody is altered relative to that of the unmodified antibody~~, and wherein

the variable region from daclizumab comprises a mature light chain variable region of SEQ ID NO:118 and a mature heavy chain variable region of SEQ ID NO: 122.

2. (currently amended) The modified antibody according to Claim 1, wherein said heavy chain constant region is that of IgG1.

3. (currently amended) An antibody comprising a variable region from daclizumab and a heavy chain constant region ~~substantially~~ at least 95% identical to that of a naturally occurring class IgG antibody wherein

~~at least~~ amino acid residue 250, EU numbering, is glutamic acid or glutamine and amino acid residue 428, EU numbering, is leucine or phenylalanine and different from ~~that~~ residues 250 and 428 as present in the naturally occurring class IgG antibody,

the FcRn binding affinity and/or serum half-life of said antibody is altered relative to the naturally occurring antibody, and

the variable region from daclizumab comprises a mature light chain variable region of SEQ ID NO:118 and a mature heavy chain variable region of SEQ ID NO: 122.

4. (cancel)

5. (previously presented) An antibody comprising a variable region from daclizumab and a heavy chain constant region, wherein:

(a) amino acid residue 250 from the heavy chain constant region is glutamic acid or glutamine;

(b) amino acid residue 428 from the heavy chain constant region is phenylalanine or leucine; and

(c) the variable region from daclizumab comprises a mature light chain variable region of SEQ ID NO:118 and a mature heavy chain variable region of SEQ ID NO: 122.

6. (original) The antibody according to Claim 3, wherein said amino acid residue 250 from the heavy chain constant region is glutamine.

7. (original) The antibody according to Claim 3, wherein said amino acid residue 428 from the heavy chain constant region is leucine.

8. (original) The antibody according to Claim 3, wherein:

said amino acid residue 250 from the heavy chain constant region is glutamic acid and said amino acid residue 428 from the heavy chain constant region is phenylalanine;

said amino acid residue 250 from the heavy chain constant region is glutamine and said amino acid residue 428 from the heavy chain constant region is phenylalanine; or

said amino acid residue 250 from the heavy chain constant region is glutamine and said amino acid residue 428 from the heavy chain constant region is leucine.

9-12. (canceled)

13. (previously presented) A modified antibody of Claim 1 with an *in vivo* clearance at least about 1.3-fold lower than that of the corresponding unmodified class IgG antibody.

14-15. (cancel)

16. (currently amended) A modified therapeutic antibody comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence selected from SEQ ID NOs: ~~120,~~ 122-123, ~~125,~~ and 127-128.

17-27. (canceled)

28. (previously presented) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 122.

29. (previously presented) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 127.

30. (previously presented) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 123.

31. (previously presented) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 128.

34-37. (canceled)

38. (previously presented) The modified antibody of Claim 1 wherein said class IgG antibody is a human IgG1.

39. pPreviously presented) The modified antibody of Claim 1 wherein said class IgG antibody is a human IgG2M3.

40. (previously presented) The antibody of Claim 3 wherein said class IgG antibody is a human IgG1.

41. (previously presented) The antibody of Claim 3 wherein said class IgG antibody is a human IgG2M3.